Koninklijke Phil Stock Price, News & Analysis

Royal Philips (NYSE: PHG) launched Philips Image Management 15 with a next-generation, zero-footprint web diagnostic viewer that delivers desktop-level radiology capabilities in a standard browser.

The viewer offers high-performance server-side rendering, advanced clinical tools, native integration with an interactive reporting module, AI tool interfaces, and optional on-premises or cloud deployment via Philips HealthSuite on AWS. It is offered as a SaaS solution and is available in the USA today for select customers, with broader regional expansion planned for 2026.

Royal Philips (NYSE: PHG) on November 19, 2025 announced an extended partnership with Cortechs.ai to integrate Cortechs.ai’s AI-enabled NeuroQuant quantitative neuroimaging analytics into Philips MR workflows.

The companies plan to embed brain volumetrics, lesion quantification and tumor tracking into Philips MR systems via the cloud-based Smart Reading environment to deliver automated, zero-click quantitative reports to clinicians, aiming to improve speed, reproducibility and diagnostic confidence while addressing radiology workforce pressures.

NeuroQuant is currently available on Philips Advanced Visualization Workspace; Smart Reading integration is a work in progress and not yet available in any jurisdiction.

Philips (NYSE: PHG) on November 17, 2025 introduced DeviceGuide, an AI-powered device-tracking solution on the EchoNavigator platform that assists physicians during minimally invasive mitral valve repair (M-TEER).

DeviceGuide combines live echo and X-ray to generate a real-time 3D model of the repair device, helping clinicians visualize device position and orientation inside the beating heart. It was developed with Edwards Lifesciences and will be previewed at London Valves 2025. Availability depends on local regulatory clearance and DeviceGuide is currently intended for use only with the Edwards PASCAL Ace mitral TEER device.

Philips (NYSE:PHG) reported Q3 2025 results showing continued momentum: comparable order intake +8%, group sales €4.3 billion (comparable sales +3.3%), and adjusted EBITA margin 12.3% (up 50 bps). Income from operations was €330 million. Free cash flow rose to €172 million and operating cash flow was €327 million. Productivity measures delivered €222 million of quarterly savings and the company remains on track for its three-year €2.5 billion productivity program.

Philips reiterated full‑year 2025 guidance, now expected toward the upper end of the adjusted EBITA margin range, and highlighted product launches, clinical trial results and sustainability validation by SBTi.

Philips (NYSE: PHG) announced support for the Forever Promise Project, an initiative connecting families of fallen World War II U.S. service members with Dutch adopters of graves at the Netherlands American Cemetery in Margraten.

Philips will help advance efforts to connect all 10,000 American families with Dutch adopters and offer employee volunteer opportunities to support remembrance activities and foster cross‑border relationships.

Hoag (partnering with Royal Philips, NYSE: PHG) announced a 10-year strategic collaboration to standardize and modernize patient monitoring across its two acute care hospitals and the expanded Sun Family Campus in Irvine, which will add 155 inpatient beds in mid-2026. Hoag will adopt Philips Enterprise Monitoring as a Service (EMaaS) and deploy IntelliVue MX750 bedside and X3 transport monitors plus the Philips Patient Information Center (PIC iX).

The integrated solution delivers continuous monitoring, early warning scores, analytics, and EHR interoperability to support clinical efficiency, patient safety and financial predictability for ongoing innovation access.

Royal Philips (NYSE:PHG) reported late-breaking 3-year results from the iMODERN trial (n=1,146) showing no significant difference in the primary composite endpoint (death, recurrent MI, or heart failure hospitalization) between immediate iFR-guided multivessel treatment during primary PCI and staged CMR-guided treatment within 4 days–6 weeks. Results were published in The New England Journal of Medicine and presented at TCT 2025. Complementary ILIAS ANOCA data (n=153) showed a sustained mean +9.4-point Seattle Angina Questionnaire gain at 6 months with ad-hoc coronary function testing and tailored therapy, with no procedure-related major events.

Royal Philips (NYSE:PHG) announced at TCT 2025 an industry-first integration that links pre-operative CT (AVW) with the Azurion image-guided therapy platform to automatically synchronize CT 3D reconstructions with C-arm movement. The feature, called Follow C-arm, rotates the CT volume in real time to match C-arm angulation, aiming to combine CCTA anatomical detail with live X-ray guidance and support a shift toward CT-guided PCI.

The release notes prior publications associating CCTA use with reduced contrast and radiation, and reiterates Azurion’s global footprint of more than 6.4 million patients treated annually in 80+ countries.

Royal Philips (NYSE: PHG) announced the 5,000th installation of its Zenition mobile C-arm system on October 8, 2025 at Kolín Regional Hospital in the Czech Republic.

Since launch in 2019, Zenition is deployed in 170+ countries and Philips reports its mobile C-arms help treat more than 15 million patients annually. The platform highlights features such as Position Memory and BodySmart software, with user tests cited showing a 45% reduction in C-arm repositioning.